PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor
Open Access
- 1 December 2009
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 11 (6) , 725-736
Abstract
We investigated the activation of platelet-derived growth factor (PDGF) receptor A (PDGFRA), PDGF receptor B (PDGFRB), epidermal growth factor receptKeywords
This publication has 39 references indexed in Scilit:
- EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapyNeuro-Oncology, 2008
- PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patientsAnnals of Oncology, 2008
- Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumorsMolecular Cancer Therapeutics, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008
- PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patientsBritish Journal of Cancer, 2007
- EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancerAnnals of Oncology, 2006
- Malignant peripheral nerve sheath tumorsCancer, 2006
- Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivityCarcinogenesis, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- TP53 mutations are frequent in malignant NFI tumorsGenes, Chromosomes and Cancer, 1994